Mississippi legislation · 2026 Regular Session
Mississippi HB565: Health benefit plans and Medicaid; require to offer coverage for biomarker testing.
Status: Signed into law, March 16, 2026
AN ACT TO BE KNOWN AS THE "JILL GARY EURE ACT" OR "JILL'S LAW"; TO REQUIRE EACH HEALTH BENEFIT PLAN, CONTRACT OR AGREEMENT THAT IS ENTERED INTO OR RENEWED ON OR AFTER JULY 1, 2026, INCLUDING THE MEDICAID PROGRAM AND THE STATE AND SCHOOL EMPLOYEES HEALTH INSURANCE PLAN, TO OFFER COVERAGE FOR BIOMARKER TESTING FOR THE PURPOSES OF DIAGNOSIS, TREATMENT, APPROPRIATE MANAGEMENT, OR ONGOING MONITORING OF AN ENROLLEE'S DISEASE OR CONDITION WHEN USE OF THE TEST IS SUPPORTED BY MEDICAL AND SCIENTIFIC EVIDENCE; TO AMEND SECTIONS 43-13-117 AND 83-5-907, MISSISSIPPI CODE OF 1972, TO CONFORM TO THE PROVISIONS OF THIS ACT; AND FOR RELATED PURPOSES.
What the bill says
An act to be known as the "jill gary eure act" or "jill's law"; to require each health benefit plan, contract or agreement that is entered into or renewed on or after july 1, 2026, including the medicaid program and the state and school employees health insurance plan, to offer coverage for biomarker testing for the purposes of diagnosis, treatment, appropriate management, or ongoing monitoring of an enrollee's disease or condition when use of the test is supported by medical and scientific evidence…
From the enrolled text, March 6, 2026:
AN ACT TO BE KNOWN AS THE "JILL GARY EURE ACT" OR "JILL'S LAW"; TO REQUIRE EACH HEALTH BENEFIT PLAN, CONTRACT OR AGREEMENT THAT IS ENTERED INTO OR RENEWED ON OR AFTER JULY 1, 2026, INCLUDING THE MEDICAID PROGRAM AND THE STATE AND SCHOOL EMPLOYEES HEALTH INSURANCE PLAN, TO OFFER COVERAGE FOR BIOMARKER TESTING FOR THE PURPOSES OF DIAGNOSIS, TREATMENT, APPROPRIATE MANAGEMENT, OR ONGOING MONITORING OF AN ENROLLEE'S DISEASE OR CONDITION WHEN USE OF THE TEST IS SUPPORTED BY MEDICAL AND SCIENTIFIC EVIDENCE; TO AMEND SECTIONS 43-13-117 AND 83-5-907, MISSISSIPPI CODE OF 1972, TO CONFORM TO THE PROVISIONS OF THIS ACT; AND FOR RELATED PURPOSES. BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MISSISSIPPI: SECTION 1. This act shall be known and may be cited as the "Jill Gary Eure Act" or "Jill's Law". SECTION 2. As used in Sections 2 and 3 of this act, the following terms shall be defined as provided in this section: (a) "Biomarker" means a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes or pharmacologic responses to a specific therapeutic intervention, including known gene-drug interactions for medications being considered for use or already being administered. Biomarkers include, but are not *HR43/R1300PH* H. B. No. 565 ~ OFFICIAL ~ G1/2 26/HR43/R1300PH PAGE 1 (RF\KP) limited …